LADENBURG THALM/SH SH assumed coverage on shares of Immunome (NASDAQ:IMNM) in a research note issued to investors on Monday morning, The Fly reports. The brokerage issued a buy rating on the stock.
Shares of IMNM stock opened at $11.55 on Monday. Immunome has a 1-year low of $10.18 and a 1-year high of $16.77.
In other Immunome news, Director Michael Rapp bought 83,332 shares of Immunome stock in a transaction dated Tuesday, October 6th. The stock was acquired at an average cost of $12.00 per share, with a total value of $999,984.00. Following the purchase, the director now directly owns 555,554 shares in the company, valued at approximately $6,666,648. The acquisition was disclosed in a filing with the SEC, which is available at this link.
Immunome Company Profile
Immunome Inc, a biotechnology company, discovers, develops, and commercializes highly targeted and native human cancer antibodies against universal cancer antigens. Its RealMAb technology enables the discovery of novel antigens and the cognate native human antibodies that target antigens; and ScreenMab multiplex functional screening technology identifies monoclonal antibodies that have exquisite for tumor neoantigens.
See Also: Channel Trading
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.